This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix reports $44.7 million net loss in 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix reported a net loss of $44.7 million, or $1.80 per share, in 2016 compared with a net loss of $39.7 million, or $1.71 per share, in 2015, according to a company press release.

Fourth quarter net loss equaled $12.8 million, or $0.52 per share, compared with a net loss of $10.6 million, or $0.43 per share, in the same period last year.

Revenue totaled $0.5 million in the fourth quarter and $1.9 million in 2016, attributed to product sales of ReSure Sealant and agreements with corporate partners.

Operating expenses increased from $39.9 million in 2015 to $45.2 million in 2016, and research and development costs increased from $26.6 million to $27.1 million.